Search

Displaying results 1481 - 1490 of 6835 in total
  1. Drug

    Cefmetazole

    go.drugbank.com/drugs/DB00274
    Approved

    It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.

  2. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    [A257330] In February 2023, the use of sparsentan to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression was approved by the FDA under … [A257325,A257335,L45310] Compared to [irbesartan], sparsentan reduces proteinuria to a greater extent.

  3. Drug

    Ticlopidine

    go.drugbank.com/drugs/DB00208
    Approved

    It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. … The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they

  4. Drug

    Sotatercept

    go.drugbank.com/drugs/DB12118
    ApprovedInvestigational

    [A263481] Sotatercept was approved by the European Commission on August 26, 2024.[L51549] … [L50361] Sotatercept works to resolve the imbalance in activin–growth differentiation factor and BMP pathway signalling observed in PAH.

  5. Drug

    N-Acetylglucosamine

    go.drugbank.com/drugs/DB00141
    ApprovedInvestigationalNutraceutical

    The N-acetyl derivative of glucosamine.

    Mixtures: Cheon Shim Bo Yun
  6. Drug

    Bezlotoxumab

    go.drugbank.com/drugs/DB13140
    Approved

    [L46976] First approved by the FDA on October 21, 2016,[A260106] bezlotoxumab is used to reduce the recurrence of _C. difficile_ infection. … [A260106] The drug was granted full approval by the EMA on January 18, 2017.[L47191]

  7. Drug

    Sitagliptin

    go.drugbank.com/drugs/DB01261
    ApprovedInvestigational

    The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. … Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256

    Mixtures: CO-SIGLAVITAE
  8. Drug

    Crizotinib

    go.drugbank.com/drugs/DB08865
    ApprovedInvestigational

    [A250785] Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.[L42460] … [A250785] Crizotinib was the first-in-class drug used to treat ALK-positive tumors.

  9. Drug

    Deflazacort

    go.drugbank.com/drugs/DB11921
    Approved

    [A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7. … Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD).

  10. Drug

    Baloxavir marboxil

    go.drugbank.com/drugs/DB13997
    ApprovedInvestigational

    [L4779] It was also approved by the European Commission on January 7, 2021.[L45241] … Baloxavir marboxil is an antiviral drug used to treat influenza. More specifically, it is a first-in-class cap-dependent endonuclease inhibitor that works to block influenza virus proliferation.